Philip Morris International
PM
$200.50
+4.05%
Philip Morris International Inc. is a global tobacco and nicotine company that sells cigarettes and reduced-risk products — including heat sticks, vapes, and oral nicotine pouches — primarily outside the United States, following its 2008 spin-off from Altria. The company is a dominant player in international tobacco, with category-leading brands such as Marlboro in combustibles and IQOS in heated tobacco, and it expanded its reduced-risk portfolio through the 2023 acquisition of Swedish Match, which brought the fast-growing Zyn nicotine pouch brand into its fold. The current investor narrative centers on PMI's transformation from a declining cigarette business into a smoke-free growth story, with reduced-risk products now contributing roughly 41% of quarterly revenue and growing at a double-digit pace. Debate among investors focuses on whether the premium valuation already reflects this transition, the sustainability of Zyn's U.S. momentum amid FDA regulatory scrutiny of nicotine pouches, and the company's ability to offset combustible volume declines with pricing power and margin expansion. Recent headlines about the FDA's nicotine pouch decision and competitive threats from smaller players like Turning Point Brands underscore the regulatory and competitive risks that frame the bull-bear debate.…
PM
Philip Morris International
$200.50
Related headlines
Investment Opinion: Should I buy PM Today?
Based on the synthesized data, PM warrants a 'Buy' rating with a 12-month horizon. The core thesis is that PM's transformation into a smoke-free growth story, driven by reduced-risk products now at 41.5% of revenue, justifies its premium valuation and offers attractive total return potential. The analyst consensus is 'Buy' with a mean rating of 1.69 and an average target price of $208.13, implying 11.0% upside from the current $187.46.
The supporting evidence is compelling: revenue grew 10.37% YoY in Q2 2026 to $11.19 billion, with net margin expanding to 25.17% from 20.66% in Q4 2025. Free cash flow is robust at $12.72 billion TTM, providing ample coverage for the 3.46% dividend yield. The forward PE of 20.40x is below the trailing PE of 22.06x, and the PEG ratio of 0.365 suggests the stock is undervalued relative to its expected earnings growth of 12.05%. Compared to the sector's forward average of 16x, PM's premium is justified by its superior growth and margins.
Key risks include regulatory actions on nicotine pouches, which could slow Zyn's growth, and the stock's premium valuation, which leaves little room for disappointment. A downgrade to 'Hold' would be warranted if revenue growth decelerates below 8% or if the FDA imposes stringent restrictions on nicotine pouches. Conversely, an upgrade to 'Strong Buy' would require accelerating smoke-free adoption and clarity on the regulatory front. Relative to its own history, PM's PE of 22.06x is near the middle of its 5-year range, suggesting the stock is fairly valued, but the growth trajectory and cash flow generation make it an attractive long-term holding.
Sign up to view all
PM 12-Month Price Forecast
The forward-looking view for PM is bullish, supported by its successful transition to reduced-risk products, strong cash flow generation, and attractive dividend yield. The company's ability to grow revenue at double-digit rates while expanding margins demonstrates operational strength. However, the premium valuation and regulatory risks surrounding nicotine pouches warrant a medium confidence level. An upgrade to high confidence would require clearer FDA guidance and sustained acceleration in Zyn sales; a downgrade would occur if revenue growth falls below 8% or if regulatory actions significantly impair the smoke-free portfolio.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $208.13 and implied upside of +3.8% versus the current price.
Average Target
$208.13
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $230
Analyst target range
PM is covered by 15 analysts, with a consensus recommendation of "Buy" (mean rating of 1.69 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $208.13, implying approximately 11.0% upside from the current price of $187.46. The consensus leans bullish, supported by the distribution of ratings: recent institutional ratings show a mix of Buy/Overweight (Citigroup, Barclays, Morgan Stanley, Needham, Stifel) and Neutral (UBS), with no Sell ratings. This suggests that while analysts see upside, there is some caution around the stock's premium valuation and regulatory risks. The target price range spans from a low of $175.00 to a high of $230.00, a spread of $55.00 or 29.4% of the average target, indicating moderate uncertainty. The high target of $230.00 implies a 22.7% upside and likely assumes accelerating growth in reduced-risk products, successful expansion of Zyn, and multiple expansion as the market rewards PM's transition. The low target of $175.00 represents a 6.6% downside and likely prices in margin compression, slower smoke-free adoption, or adverse regulatory outcomes. The estimated EPS average of $12.05 for the coming year, with a range of $11.79 to $12.49, suggests analysts expect solid earnings growth. Recent analyst actions have been mostly reiterations of existing ratings rather than upgrades or downgrades, indicating stable sentiment. The relatively tight spread between the low and high targets (excluding the high outlier) suggests reasonable conviction among analysts, though the wide range from $175 to $230 reflects differing views on the pace of the smoke-free transition and regulatory environment.
Bulls vs Bears: PM Investment Factors
The bull case for PM rests on its successful transition to reduced-risk products, which now contribute 41.5% of revenue and are growing at a double-digit pace, driving margin expansion and solid free cash flow. The bear case centers on the stock's premium valuation relative to the sector, regulatory risks surrounding nicotine pouches, and the persistent decline in combustible volumes. Currently, the bull evidence appears stronger, given the company's consistent revenue growth, margin improvement, and analyst consensus 'Buy' rating with 11% upside to the average target. However, the most critical tension is the sustainability of Zyn's growth amid FDA scrutiny; a negative regulatory outcome could significantly undermine the growth narrative and justify a lower valuation multiple.
Bullish
- Smoke-Free Products Drive Growth: Reduced-risk products generated $4.65 billion in Q2 2026, representing 41.5% of total revenue, and are growing at a double-digit pace. This mix shift is transforming PM from a declining tobacco company into a growth story, with total revenue up 10.37% YoY to $11.19 billion.
- Strong Profitability and Cash Flow: Q2 2026 net margin was 25.17%, up from 20.66% in Q4 2025, while operating margin improved to 40.48% from 32.55% over the same period. Free cash flow remains robust at $12.72 billion TTM, comfortably covering the $2.30 billion quarterly dividend.
- Attractive Dividend and Valuation: The stock offers a 3.46% dividend yield with a payout ratio of 76%, and trades at a forward PE of 20.40x, below its trailing PE of 22.06x. The PEG ratio of 0.365 suggests undervaluation relative to expected earnings growth of 12.05%.
- Analyst Consensus and Upside: 15 analysts rate PM a 'Buy' with a mean rating of 1.69, and the average target price of $208.13 implies 11.0% upside from the current $187.46. The high target of $230.00 suggests 22.7% upside if growth accelerates.
Bearish
- Premium Valuation vs. Sector: PM trades at a trailing PE of 22.06x, a premium to the Consumer Defensive sector average of 15-18x. The forward PE of 20.40x is 27.5% above the sector's forward average of 16x, leaving little room for error if growth slows.
- Regulatory Risks in Nicotine Pouches: The FDA's recent nicotine pouch decision introduces uncertainty for Zyn, a key growth driver. Stricter regulations could limit marketing, flavors, or sales, potentially slowing the reduced-risk product momentum that underpins the bull case.
- Combustible Volume Declines: Combustible products still account for 58.5% of revenue ($6.55 billion in Q2 2026) but face structural volume declines. The company relies on pricing power to offset these declines, which may become harder as consumers shift to alternatives.
- Negative Equity and High Leverage: The debt-to-equity ratio is -4.89 due to negative shareholders' equity from aggressive buybacks and dividends. While free cash flow is strong, the balance sheet offers limited flexibility in a downturn, and the current ratio of 0.958 indicates tight liquidity.
PM Technical Analysis
PM is in a sustained uptrend, with the stock up 18.71% over the past year and 16.94% year-to-date, though it has pulled back modestly from its 52-week high of $207.76. At the current price of $187.46, the stock is trading at approximately 69% of its 52-week range (calculated as ($187.46 - $142.11) / ($207.76 - $142.11)), positioning it in the upper-middle portion of its annual range. This suggests the stock retains positive momentum but is not overextended at the highs, leaving room for either a breakout or further consolidation. The 52-week low of $142.11 represents a 24.2% drawdown from current levels, highlighting the downside risk if the trend reverses. Recent momentum has been mixed: the stock is down 0.26% over the past month and up 2.85% over three months, indicating a deceleration from the stronger 18.57% six-month gain. This divergence — a flat 1-month performance against a robust 1-year trend — suggests a temporary pause or consolidation phase rather than a trend reversal, especially given the stock's relative strength of -0.85% versus SPY over the past month. The 3-month relative strength of -0.49% versus SPY further confirms that PM has slightly underperformed the market recently, though its 1-year relative strength of +3.70% shows it remains a long-term outperformer. Key technical levels to watch include support at the 52-week low of $142.11 and resistance at the 52-week high of $207.76. A breakout above $207.76 would signal renewed momentum and likely attract trend-following capital, while a breakdown below $142.11 would indicate a significant bearish shift and potential for further downside. With a beta of 0.395, PM is significantly less volatile than the broader market — roughly 60% less volatile than SPY — making it a defensive holding that may appeal to risk-averse investors but could lag in strong bull markets. The max drawdown of -19.26% over the past year further illustrates the stock's relatively contained risk profile compared to higher-beta equities.
Beta
0.36
0.36x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+29.1%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +1.0% |
| 3m | +10.4% | +2.5% |
| 6m | +25.0% | +13.9% |
| 1y | +29.1% | +15.0% |
| ytd | +25.1% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory remains solidly positive, with Q2 2026 revenue of $11.19 billion representing 10.37% year-over-year growth from $10.14 billion in Q2 2025. This continues a multi-quarter trend of consistent growth: Q1 2026 revenue was $10.15 billion (up 9.1% from $9.30 billion in Q1 2025), Q4 2025 was $10.36 billion (up 6.7% from $9.71 billion in Q4 2024), and Q3 2025 was $10.85 billion (up 9.4% from $9.91 billion in Q3 2024). The growth is being driven by reduced-risk products, which generated $4.65 billion in Q2 2026 (41.5% of total revenue) versus $6.55 billion from combustible products, reflecting the ongoing mix shift toward smoke-free alternatives. This accelerating top-line momentum supports the investment case for PM as a transitioning growth story rather than a declining tobacco company. Profitability remains robust, with Q2 2026 net income of $2.82 billion and a net margin of 25.17%, up from 24.03% in Q1 2026 and 20.66% in Q4 2025. Gross margin stood at 68.43% in Q2 2026, consistent with the 68.06% in Q1 2026 and 65.64% in Q4 2025, indicating stable pricing power and cost management. Operating margin was 40.48% in Q2 2026, a significant improvement from 32.55% in Q4 2025, driven by higher revenue and effective cost control. The company's EBITDA margin has remained healthy at around 40-43% over recent quarters, underscoring the cash-generative nature of the business despite volume declines in traditional cigarettes. PM's balance sheet shows a current ratio of 0.958, slightly below 1.0, indicating that current liabilities marginally exceed current assets — a common characteristic of tobacco companies that prioritize shareholder returns. The debt-to-equity ratio is negative (-4.89) due to negative shareholders' equity, a result of aggressive share buybacks and dividends over time, which complicates traditional leverage analysis. However, free cash flow remains strong: TTM free cash flow was $12.72 billion, with Q2 2026 free cash flow of $5.11 billion and operating cash flow of $5.49 billion. The company paid $2.30 billion in dividends in Q2 2026, comfortably covered by operating cash flow, and its FCF yield (based on market cap of $249.6 billion) is approximately 5.1%, indicating solid cash generation relative to its valuation. The negative ROE of -113.55% is a direct consequence of negative equity and should not be interpreted as a sign of operational weakness; ROA of 14.59% provides a clearer picture of profitability.
Quarterly Revenue
$11.2B
2026-06
Revenue YoY Growth
+10.4%
YoY Comparison
Gross Margin
68.4%
Latest Quarter
Free Cash Flow
$12.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
With positive net income of $2.82 billion in Q2 2026, the PE ratio is the appropriate primary valuation metric. PM trades at a trailing PE of 22.06x and a forward PE of 20.40x, with the forward multiple lower than the trailing one, implying the market expects earnings growth over the next year. The PEG ratio of 0.365 is notably low, suggesting that the stock is undervalued relative to its expected earnings growth rate, though this metric can be volatile for companies with irregular growth. The PS ratio of 6.14x and EV/EBITDA of 16.81x provide additional context, with the EV/EBITDA multiple reflecting the company's substantial debt load. Compared to the broader Consumer Defensive sector, where tobacco companies often trade at a discount to the market due to regulatory and volume risks, PM's trailing PE of 22.06x represents a premium to the sector average (typically 15-18x). However, this premium is justified by PM's superior growth profile (10.4% revenue growth), higher margins (67.1% gross margin, 36.7% operating margin), and leadership in reduced-risk products. The forward PE of 20.40x versus the sector's forward average of approximately 16x implies a 27.5% premium, which is supported by PM's estimated EPS growth of 12.05% for the coming year. Historically, PM's PE ratio has ranged from a low of 15.3x (Q3 2024) to a high of 29.3x (Q4 2025), with the current 22.06x sitting near the middle of that range. The PS ratio of 6.14x is significantly lower than its historical average of around 20x (based on quarterly data from 2021-2025), but this discrepancy is due to the different revenue base used in the historical ratios (which appear to be based on quarterly revenue annualized differently). More relevant is the PE trend: the current 22.06x is above the 2023-2024 average of approximately 17-18x but below the 2025 peak of 29.3x, suggesting the stock is neither cheap nor expensive relative to its own history. The dividend yield of 3.46% remains attractive for income investors, though the payout ratio of 76.0% indicates limited room for significant dividend increases without earnings growth.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for PM are primarily tied to its capital structure and reliance on pricing power. The company operates with negative shareholders' equity, reflected in a debt-to-equity ratio of -4.89, a result of years of aggressive share buybacks and dividends. While free cash flow of $12.72 billion TTM comfortably covers the $2.30 billion quarterly dividend, the payout ratio of 76% limits flexibility for significant dividend increases without earnings growth. Additionally, the current ratio of 0.958 indicates that current liabilities slightly exceed current assets, which could pose liquidity concerns if cash flow deteriorates. The company's heavy dependence on combustible products, which still generate 58.5% of revenue, exposes it to structural volume declines that must be offset by pricing and cost controls.
Market and competitive risks include valuation compression and regulatory headwinds. PM trades at a forward PE of 20.40x, a 27.5% premium to the sector's forward average of 16x, which assumes continued strong growth in reduced-risk products. If growth slows or regulatory actions restrict the nicotine pouch market, the multiple could contract toward the sector average, implying a 20-25% downside. The FDA's recent scrutiny of nicotine pouches, as highlighted in recent news, poses a direct threat to Zyn's U.S. momentum. Competitive threats from smaller players like Turning Point Brands, which are also vying for market share in nicotine pouches, could pressure PM's pricing and market position. With a beta of 0.395, PM is less sensitive to market swings, but sector rotation away from defensive stocks in a strong bull market could lead to underperformance.
The worst-case scenario would involve a combination of regulatory crackdowns on nicotine pouches, accelerated combustible volume declines, and a broader market rotation away from defensive sectors. In this scenario, PM's growth narrative would unravel, leading to multiple compression and earnings misses. The stock could retest its 52-week low of $142.11, representing a 24.2% decline from the current price of $187.46. The analyst low target of $175.00 implies a 6.6% downside, but in a severe bear case, the stock could fall to the low $140s, a loss of approximately 24% from current levels. This would be consistent with the max drawdown of -19.26% observed over the past year, though a more severe outcome is possible if regulatory risks materialize.
FAQ
The most severe risk is regulatory intervention in the nicotine pouch market, as the FDA's recent scrutiny could restrict Zyn's growth and limit PM's expansion. Financial risks include negative shareholders' equity (debt-to-equity of -4.89) and a current ratio below 1.0, which could constrain financial flexibility. Competitive risks arise from smaller players like Turning Point Brands gaining share in nicotine pouches, potentially pressuring pricing. Macroeconomic risks are lower due to PM's low beta of 0.395, but a strong bull market could lead to underperformance as investors rotate to higher-beta stocks. Additionally, combustible volume declines, which still represent 58.5% of revenue, pose a structural headwind.
The 12-month forecast for PM includes a base case (55% probability) with a target range of $200-$215, assuming steady revenue growth of 8-10% and no major regulatory disruptions. The bull case (25% probability) targets $220-$230, driven by accelerating smoke-free adoption and favorable FDA decisions. The bear case (20% probability) targets $150-$175, reflecting regulatory crackdowns and competitive pressures. The most likely scenario is the base case, with the key assumption that reduced-risk products continue to grow at a double-digit pace and margins remain stable. The analyst average target of $208.13 aligns with the base case.
PM appears fairly valued to slightly undervalued relative to its growth prospects. The trailing PE of 22.06x is above the sector average of 15-18x, but the forward PE of 20.40x and PEG ratio of 0.365 suggest the market is not fully pricing in expected earnings growth of 12.05%. The stock's PE is near the middle of its 5-year range, indicating a balanced valuation. Compared to peers, PM's premium is justified by its higher revenue growth (10.37% YoY) and superior margins (67.1% gross margin). The market expects continued double-digit growth in reduced-risk products, and any slowdown could lead to multiple compression.
PM presents a favorable risk/reward profile for investors seeking a combination of income and growth. The stock offers an 11.0% upside to the analyst average target of $208.13, supported by a 3.46% dividend yield and a forward PE of 20.40x. The biggest downside risk is regulatory action on nicotine pouches, which could push the stock toward the 52-week low of $142.11, a 24.2% decline. However, with a beta of 0.395, PM is less volatile than the market, making it suitable for conservative investors. It is a good buy for those with a long-term horizon who believe in the smoke-free transition, but investors should be aware of the premium valuation and regulatory uncertainties.
PM is best suited for long-term investment, given its defensive characteristics, stable dividend, and ongoing business transformation. The low beta of 0.395 and consistent free cash flow make it a low-volatility holding, but the premium valuation and regulatory risks could lead to short-term volatility. The dividend yield of 3.46% and payout ratio of 76% appeal to income-focused investors. Earnings visibility is moderate, with analysts estimating EPS of $12.05 for the coming year. A minimum holding period of 2-3 years is recommended to allow the smoke-free transition to fully materialize and to ride out potential regulatory headwinds. Short-term trading is less advisable due to the stock's low volatility and recent momentum deceleration.